AB

Akash Bhagwat Shelke

Active Director Additional Director DIN 10217924
DIN 10217924 First appointment Mar 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Akash Bhagwat Shelke

Data last updated:

Akash Bhagwat Shelke is an Additional Director at Carvicare Pharmaceutical Private Limited (since 2024). The company operates in Pharma.

DIN 10217924
Primary Designation Additional Director
Industry Pharma
First Appointment 19 Mar 2024
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Additional Director19 Mar 20242022Active

Directorship timeline

Open interactive timeline →
Carvicare Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Akash Bhagwat Shelke

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Akash Bhagwat Shelke

Akash Bhagwat Shelke currently holds 1 directorship: Carvicare Pharmaceutical Private Limited (Additional Director, since 19 Mar 2024).

Akash Bhagwat Shelke was first appointed on 19 Mar 2024 as Additional Director at Carvicare Pharmaceutical Private Limited.

The current boards of Akash Bhagwat Shelke's companies include Deepak Kundlik Nachan (Carvicare Pharmaceutical Private Limited), Priyanka Tanaji Pondkule (Carvicare Pharmaceutical Private Limited), Sagar Ramchandra Pondkule (Carvicare Pharmaceutical Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available